HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Niacin Supplement For High Cholesterol Targeted In Warning Letter

This article was originally published in The Tan Sheet

Executive Summary

Upsher-Smith Labs' Slo-Niacin was cited by FDA in a recent warning letter for claims it has made to treat hypercholesterolemia

You may also be interested in...



Upsher-Smith warning letter

Originally posted on FDA's Web site, warning letter for firm's Slo-Niacin supplement was rescinded and eventually removed from site because it had not been approved through appropriate FDA channels, according to counsel for Upsher-Smith. All warning letters are now being reviewed by the agency's Office of Chief Counsel before they are released. 1"The Tan Sheet" Oct. 7, 2002, p. 16 cited a warning letter deeming Slo-Niacin a misbranded new drug...

Ammonium Lactate 12% Drug Ingredient Requiring FDA Approval – Petition

Two recent ANDA approvals for products containing ammonium lactate 12% reflect FDA's position that the skin care ingredient is a drug, Paddock Labs says in a Sept. 5 citizen petition

FDA Warning Letters Increasingly Targeting Internet Claims

More than 80% of the warning letters concerning OTC drug and dietary supplement products sent in the last few months have focused on Internet claims

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS130877

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel